Literature DB >> 16611876

Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response?

B E Joven, R Almodóvar, M Galindo, I Mateo, J L Pablos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16611876      PMCID： PMC1798136          DOI： 10.1136/ard.2005.040055

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Role of cytokines in rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

3.  Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy.

Authors:  M G Helliwell; G S Panayi; A Unger
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

4.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

5.  TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection.

Authors:  Anna Zganiacz; Michael Santosuosso; Jun Wang; Tony Yang; Lihao Chen; Maria Anzulovic; Scott Alexander; Brigitte Gicquel; Yonghong Wan; Jonathan Bramson; Mark Inman; Zhou Xing
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

6.  Impaired delayed type cutaneous hypersensitivity in rheumatoid arthritis reversed by chrysotherapy.

Authors:  M D Smith; A Smith; J O'Donnell; M J Ahern; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

7.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
  7 in total
  5 in total

1.  TNF-alpha antagonist therapy modify the tuberculin skin test response.

Authors:  Tulin Cagatay; Zeki Kilicaslan; Penbe Cagatay; Munevver Mertsoylu; Ziya Gulbaran; Reyhan Yildiz; Leyla Pur; Sevil Kamali; Ahmet Gul
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

2.  Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment.

Authors:  M Bocchino; A Matarese; B Bellofiore; P Giacomelli; G Santoro; N Balato; F Castiglione; R Scarpa; F Perna; G Signoriello; D Galati; A Ponticiello; A Sanduzzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-10       Impact factor: 3.267

3.  Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.

Authors:  Alexandra Belson; Tim Schmidt; Disala Fernando; Kelly Hardes; Nicola Scott; Sara Brett; Deborah Clark; João Joaquim Oliveira; Bill Davis; Simon McHugh; John Stone
Journal:  Inflamm Res       Date:  2016-03-11       Impact factor: 4.575

4.  Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha.

Authors:  Osman Elbek; Meral Uyar; Neriman Aydin; Sermin Börekçi; Nazan Bayram; Hasan Bayram; Oner Dikensoy
Journal:  Clin Rheumatol       Date:  2008-12-04       Impact factor: 2.980

5.  Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors.

Authors:  Inbal Fuchs; Lone Avnon; Tamar Freud; Mahmoud Abu-Shakra
Journal:  Clin Rheumatol       Date:  2008-09-16       Impact factor: 2.980
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.